Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBITDA Margin: 2019-2023

Historic EBITDA Margin for ADC Therapeutics (ADCT) over the last 4 years, with Sep 2023 value amounting to -249.42%.

  • ADC Therapeutics' EBITDA Margin fell 24534.00% to -249.42% in Q3 2023 from the same period last year, while for Sep 2023 it was -241.08%, marking a year-over-year decrease of 16047.00%. This contributed to the annual value of -58.90% for FY2022, which is 71275.00% up from last year.
  • Per ADC Therapeutics' latest filing, its EBITDA Margin stood at -249.42% for Q3 2023, which was down 21.31% from -205.62% recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' EBITDA Margin registered a high of 1,361.82% during Q1 2021, and its lowest value of -162,315.79% during Q3 2020.
  • Moreover, its 3-year median value for EBITDA Margin was -249.42% (2023), whereas its average is -232.33%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by 16,231,579bps in 2020, then surged by 16,187,621bps in 2021.
  • ADC Therapeutics' EBITDA Margin (Quarterly) stood at 0.00% in 2019, then tumbled by 16,231,579bps to -162,315.79% in 2020, then soared by 16,187,621bps to -369.08% in 2021, then soared by 35,370bps to -15.38% in 2022, then crashed by 24,534bps to -249.42% in 2023.
  • Its last three reported values are -249.42% in Q3 2023, -205.62% for Q2 2023, and -271.55% during Q1 2023.